RNS Number : 6800F
ValiRx PLC
26 September 2024

26 September 2024

ValiRx PLC ("ValiRx" or the "Company")

Conclusion of Evaluation Project

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, provides the following update at the conclusion of the Evaluation project from the University of Barcelona announced on 7 June 2023.

On entering the broader collaboration agreement with Barcelona University in June 2023, the Company tested drug candidates from the series "KRAS2" in a barrage of *in silico* and *in vitro* tests. After expanding the series of molecules through *in silico* study, a selection of candidates were synthesised and tested for anti-cancer activity as a monotherapy and in combination with standard chemotherapy agents within the laboratory at Inaphaea BioLabs Limited.

Although initial results show promise, the development programme is at an early stage, and the Company has decided to return the project to the university researchers for further development, with no further financial commitment from the Company. The parties have agreed to terminate the current collaboration agreement and revert responsibility for maintaining the intellectual property to Barcelona University.

Mark Eccleston, CEO of ValiRx commented"Working alongside the University of Barcelona team on this project has been an engaging experience, and although we are not in a position to progress with this lead series of molecules at this stage, we look forward to retaining close contact with the team at Barcelona to hear further updates on these and other projects which could lead to future agreements."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

*** ENDS ***

For more information, please contact:

ValiRx plc Dr Mark Eccleston, CEO	**Tel: +44 (0) 115 784 0026** **www.valirx.com** Mark.eccleston@valirx.com
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director	**+44 (0) 115 787 0206** **www.vformation.biz** lucy@vformation.biz sue@vformation.biz
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti	**Tel: +44 (0) 20 7213 0880**
Shard Capital Partners LLP (Sole Broker) Damon Heath	**Tel: +44 (0) 20 7186 9000**

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit:www.valirx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCQKPBQPBKDQCB